Trial
NCT03425461
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
Bristol-Myers Squibb; Vaccinex Inc.; National Cancer Institute (NCI)
Condition
Metastatic Melanoma
Intervention
Anti-SEMA4D Monoclonal Antibody VX15/2503
Why stopped
funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-02